Pablo Corral Shares Insights on Remnant Cholesterol and Its Role in Atherosclerotic Cardiovascular Disease
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:
“A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Remnant cholesterol: the overlooked driver of residual risk in ASCVD
Despite achieving LDL-C targets with statins and novel lipid-lowering therapies, patients remain exposed to substantial residual cardiovascular risk. Emerging evidence highlights remnant cholesterol (RC)—the cholesterol content of triglyceride-rich lipoproteins—as a causal factor in atherosclerosis.
Epidemiological, genetic, and mechanistic studies consistently show that elevated RC predicts major adverse cardiovascular events, independently of LDL-C. Mendelian randomization confirms a causal role, while clinical data suggest that RC promotes endothelial dysfunction, inflammation, and thrombosis.
Although lifestyle interventions remain essential, pharmacologic strategies—including statins, fibrates, PCSK9 inhibitors, and novel gene-targeted therapies—can reduce RC levels. However, standardized measurement and clear therapeutic targets are still lacking.
RC should be recognized as a priority marker in cardiovascular prevention, guiding future strategies to reduce residual risk in high-risk populations”
Title: A significant presence in atherosclerotic cardiovascular disease: Remnant cholesterol: A review
Authors: Li Wang, Qingmei Zhang, Zhiyang Wu, Xiwei Huang
Read the full article here.
Stay informed with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals